tupungato/iStock via Getty Images
RAPT Therapeutics (NASDAQ:RAPT) stock rallied as much as 180% Monday after the company announced a worldwide licensing deal with China’s Shanghai Jemincare for an allergy drug candidate and a $150M private placement of its stock.
RAPT (NASDAQ:RAPT) said it